Publisher Full Text
Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic.Chest. 2020 09; 158(3):869-872.Chest
Links
MeSH
Pub Type(s)
Editorial
Research Support, Non-U.S. Gov't
Language
eng
PubMed ID
32422130
Citation
Bhutani, Mohit, et al. "Key Highlights of the Canadian Thoracic Society's Position Statement On the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic." Chest, vol. 158, no. 3, 2020, pp. 869-872.
Bhutani M, Hernandez P, Bourbeau J, et al. Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic. Chest. 2020;158(3):869-872.
Bhutani, M., Hernandez, P., Bourbeau, J., Dechman, G., Penz, E., Aceron, R., Beauchamp, M., Wald, J., Stickland, M., Olsen, S. R., & Goodridge, D. (2020). Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic. Chest, 158(3), 869-872. https://doi.org/10.1016/j.chest.2020.05.530
Bhutani M, et al. Key Highlights of the Canadian Thoracic Society's Position Statement On the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic. Chest. 2020;158(3):869-872. PubMed PMID: 32422130.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR
T1 - Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic.
AU - Bhutani,Mohit,
AU - Hernandez,Paul,
AU - Bourbeau,Jean,
AU - Dechman,Gail,
AU - Penz,Erika,
AU - Aceron,Raymond,
AU - Beauchamp,Marla,
AU - Wald,Joshua,
AU - Stickland,Michael,
AU - Olsen,Sharla-Rae,
AU - Goodridge,Donna,
Y1 - 2020/05/16/
PY - 2020/5/19/pubmed
PY - 2020/9/18/medline
PY - 2020/5/19/entrez
KW - COVID-19, coronavirus disease 2019
KW - CTS, Canadian Thoracic Society
KW - ICS, inhaled corticosteroid
KW - LABA, long-acting beta-2-agonist
KW - SARS-CoV-2, severe acute respiratory syndrome coronavirus 2
SP - 869
EP - 872
JF - Chest
JO - Chest
VL - 158
IS - 3
SN - 1931-3543
UR - https://www.unboundmedicine.com/medline/citation/32422130/Key_Highlights_of_the_Canadian_Thoracic_Society's_Position_Statement_on_the_Optimization_of_COPD_Management_During_the_Coronavirus_Disease_2019_Pandemic_
L2 - https://linkinghub.elsevier.com/retrieve/pii/S0012-3692(20)31456-2
DB - PRIME
DP - Unbound Medicine
ER -